STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1408 by analyst upside · 2026-06-27
BMRN
BioMarin Pharmaceutical Inc.
Healthcare · Market Cap $11B · P/E 41.3x
ANALYST PRICE TARGET
+48.9%
implied upside to consensus target
Current Price $59.0
Consensus Target $87.85
Bull Target $120.0
Bear Target $50.0
Analysts Covering 26
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
16
Hold
6
Sell
0
52-Week Low $49.26
52-Week High $66.28
YTD Return -0.8%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) 41.3x
Forward P/E 9.1x
EPS (TTM) $1.43
PEG Ratio 0.70
Dividend Yield N/A
Revenue (TTM) $3.2B
Profit Margin 8.3%
52-WEEK RANGE
52-Week Low $49.26
52-Week High $66.28
Current Price $59.0
Bear Target $50.0
Bull Target $120.0
● Now $59.0 ● Target $87.85
TRADING DATA
Avg Volume 2.0M
YTD Return -0.8%
Analyst Count 26
Consensus Buy
Upside to Target +48.9%
Last Updated 2026-06-27

ANALYST SUMMARY

BioMarin Pharmaceutical Inc. (BMRN) is currently trading at $59.0 with a Wall Street consensus price target of $87.85, implying potential upside of 48.9% over the next 12 months. 26 analysts currently cover BMRN, with a consensus rating of Buy - 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $120.0, while the most cautious has a target of $50.0.

BMRN operates in the Healthcare sector with a market capitalisation of $11B. The stock is down 0.8% year-to-date and is currently trading near the upper end of its 52-week range of $49.26 – $66.28.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BMRN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-05-22 Building track record
B of A Securities — Reiterated
Buy → Buy 2026-05-19 Building track record
Citigroup ● Initiated
Buy 2026-05-19 Building track record
HC Wainwright & Co. — Reiterated
Neutral → Neutral 2026-05-18 31% win rate (48 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-05-07 Building track record
Bernstein — Reiterated
Outperform → Outperform 2026-05-05 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2026-05-05 Building track record
RBC Capital reit
Sector Perform → Sector Perform 2026-05-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
25/30
Consensus clarity
6/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →